Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01510704 · ClinicalTrials.gov registry record · Phase 2
Phase II Dose-ranging Study of APD421 in PONV
A Phase 2 study, sponsored by Acacia Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
NCT01510704 is a Phase 2 study that has completed, run by Acacia Pharma. The registered enrollment target is 215 participants.
The verdict
NCT01510704, a Phase 2 study, has completed, sponsored by Acacia Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of different doses of APD421 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystectomy (any surgical technique) or "other" elective surgery scheduled to last at least one hour from induction of anaesthesia), requiring at least one overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use for post-operative analgesia.
Interventions
- DRUG Placebo
- DRUG APD421
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01510704
The ClinicalTrials.gov registry entry for NCT01510704 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acacia Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01510704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01510704 about?
NCT01510704 is a clinical study titled "Phase II Dose-ranging Study of APD421 in PONV". To assess the efficacy and safety of different doses of APD421 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystec...
What is the current status of trial NCT01510704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2012-01. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01510704?
The interventions under investigation include: Placebo (DRUG), APD421 (DRUG).
Who is sponsoring clinical trial NCT01510704?
This trial is sponsored by Acacia Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.